Prime Medicine, Inc. - Common Stock (PRME) is currently showing a slightly bullish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently weak earnings tone.
HEADLINE TAKE: There is a mild positive lean in the higher-value headlines, though the setup is not strong enough to call decisively bullish.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor
NEWS SCORE
58/100
Slightly Bullish
Bearish
Neutral
Bullish
Earnings Tone
28
Weak based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$3.49
Trend Context
Mixed / range
Latest briefing
What's happening with PRME
seekingalpha.com9 Jul 2026
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com8 Jul 2026
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
-- Arbitration tribunal declared that PM647 is within Prime Medicine's “Field”, confirming Prime Medicine's right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damages to Beam Therapeutics -- -- Prime Medicine plans to submit an IND and/or CTA filing for PM647 in Q3 2026, initial clinical data expected in 2027 -- CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com22 Jun 2026
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359's potential to address unmet need in p47 phox -deficient CGD -- -- Designation enables early and intensive FDA engagement, and provides eligibility for rolling and priority Biologics License Application review -- -- PM359 now holds RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease Designations -- CAMBRIDGE, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- P…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
18 Jun 2026
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
